Patents Assigned to Wellmarker Bio Co., Ltd.
-
Patent number: 11946934Abstract: The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.Type: GrantFiled: September 3, 2015Date of Patent: April 2, 2024Assignee: Wellmarker Bio Co., LTD.Inventors: Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin
-
Publication number: 20230346790Abstract: A pharmaceutical composition for preventing or treating cancer, which is associated with a KRAS mutation and exhibits resistance to an EGFR-targeted therapeutic agent is disclosed. The pharmaceutical composition can be useful for treatment of patients with cancer which has the KRAS mutation and exhibits resistance to cetuximab that is an anticancer therapeutic agent. A method for providing information on an anticancer treatment and/or enhancing cancer treatment by identifying a KRAS mutation and optionally additionally a RON mutation are disclosed.Type: ApplicationFiled: February 5, 2021Publication date: November 2, 2023Applicant: WELLMARKER BIO CO., LTD.Inventors: Jae-Sik SHIN, Jung-Eun LEE, Joon-Yee JEONG, Min-Ki LEE, Hyo-Jin KIM, Soon-Jin CHOI, Ji-Hyun GO
-
Publication number: 20230172914Abstract: A method for treating cancer in a patient who is resistant to a protein kinase inhibitor, administering an anticancer agent containing, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof is disclosed. Here, the patient may carry active RON. In addition, the patient may carry normal KRAS gene. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.Type: ApplicationFiled: September 6, 2019Publication date: June 8, 2023Applicant: WELLMARKER BIO CO., LTD.Inventors: Seung-Woo HONG, Jai-Hee MOON, Jae-Sik SHIN, Joseph KIM, Yoon-Sun PARK, Min-Ki LEE, Joon-Yee JEONG, So-Hee LEE, Soon-Jin CHOI
-
Publication number: 20230099204Abstract: A pharmaceutical composition that is useful preventing or treating cancer with a KRAS mutation and activated RON is disclosed. The pharmaceutical composition may be utilized as an anticancer drug that exhibits an excellent cell death-inducing ability on cancer cells with KRAS G13 mutation or KRAS G12 mutation and a RON mutation or tyrosine-phosphorylated RON (pTyr-RON).Type: ApplicationFiled: March 3, 2021Publication date: March 30, 2023Applicant: WELLMARKER BIO CO., LTD.Inventors: Jae-Sik SHIN, Young-Ok KO, Min-Ki LEE, Yong-Seok KIM, Soon-Jin CHOI, Na-Jung LIM, Min-Hwa KIM, Jun-Hyung LEE
-
Patent number: 11447500Abstract: A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.Type: GrantFiled: March 8, 2019Date of Patent: September 20, 2022Assignee: WELLMARKER BIO CO., LTD.Inventors: Hyunho Lee, Chun-Ho Park, Sun Chul Hur, Jai-Hee Moon, Jae-Sik Shin, Seung-Woo Hong, Yoon-Sun Park, Joseph Kim, Sohee Lee, Hyojin Kim, Hyebin Park
-
Publication number: 20220288043Abstract: A thienopyridine derivative compound of Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase. Therefore, a use of the compound or a pharmaceutically acceptable salt thereof in treating a disease associated with an activity of a protein kinase in a subject in need thereof is disclosed.Type: ApplicationFiled: May 26, 2022Publication date: September 15, 2022Applicant: WELLMARKER BIO CO, LTD.Inventors: Hyunho LEE, Chun-Ho PARK, Sun Chul HUR, Jai-Hee MOON, Jae-Sik SHIN, Seung-Woo HONG, Yoon-Sun PARK, Joseph KIM, Sohee LEE, Hyojin KIM, Hyebin PARK
-
Publication number: 20220235064Abstract: An oxo-pyridine fusion ring compound of chemical formula 1 or a pharmaceutically acceptable salt thereof effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines.Type: ApplicationFiled: August 3, 2020Publication date: July 28, 2022Applicant: WELLMARKER BIO CO., LTD.Inventors: Hyun RYU, Jung-Eun LEE, Young-Ok KO, Yong-Seok KIM, Hye-Bin PARK
-
Patent number: 11186873Abstract: The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.Type: GrantFiled: July 29, 2015Date of Patent: November 30, 2021Assignee: WELLMARKER BIO CO., LTD.Inventors: Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin, Seung Mi Kim, Dae Hee Lee, Eun Young Lee, Seul Lee
-
Publication number: 20210317133Abstract: A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.Type: ApplicationFiled: March 8, 2019Publication date: October 14, 2021Applicant: WELLMARKER BIO CO., LTD.Inventors: Hyunho LEE, Chun-Ho PARK, Sun Chul HUR, Jai-Hee MOON, Jae-Sik SHIN, Seung-Woo HONG, Yoon-Sun PARK, Joseph KIM, Sohee LEE, Hyojin KIM, Hyebin PARK
-
Patent number: 11008622Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.Type: GrantFiled: July 29, 2015Date of Patent: May 18, 2021Assignee: Wellmarker Bio Co., Ltd.Inventors: Tae Won Kim, Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin, Seung Mi Kim, Dae Hee Lee, Eun Young Lee, Seul Lee, Yong Sang Hong